Literature DB >> 21983871

The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC).

Lifeng Wang1, Zheng Zhang, Fu-Sheng Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21983871      PMCID： PMC4002804          DOI： 10.1038/cmi.2011.43

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  12 in total

1.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

2.  miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.

Authors:  Jinhong Chang; Emmanuelle Nicolas; Debora Marks; Chris Sander; Anthony Lerro; Marie Annick Buendia; Chunxiao Xu; William S Mason; Thomas Moloshok; Roque Bort; Kenneth S Zaret; John M Taylor
Journal:  RNA Biol       Date:  2004-07-01       Impact factor: 4.652

3.  Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data.

Authors:  G I Abelev
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

4.  MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators.

Authors:  Akemi Takata; Motoyuki Otsuka; Kentaro Kojima; Takeshi Yoshikawa; Takahiro Kishikawa; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Biochem Biophys Res Commun       Date:  2011-07-21       Impact factor: 3.575

5.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.

Authors:  Christine Esau; Scott Davis; Susan F Murray; Xing Xian Yu; Sanjay K Pandey; Michael Pear; Lynnetta Watts; Sheri L Booten; Mark Graham; Robert McKay; Amuthakannan Subramaniam; Stephanie Propp; Bridget A Lollo; Susan Freier; C Frank Bennett; Sanjay Bhanot; Brett P Monia
Journal:  Cell Metab       Date:  2006-02       Impact factor: 27.287

Review 6.  MicroRNA profiling in cancer.

Authors:  Reinhold Munker; George A Calin
Journal:  Clin Sci (Lond)       Date:  2011-08       Impact factor: 6.124

Review 7.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

8.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

9.  MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.

Authors:  Shoumei Bai; Mohd W Nasser; Bo Wang; Shu-Hao Hsu; Jharna Datta; Huban Kutay; Arti Yadav; Gerard Nuovo; Pawan Kumar; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 10.  The role of microRNAs in liver cancer progression.

Authors:  S Huang; X He
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640
View more
  3 in total

1.  A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma.

Authors:  Chen Chen; Jiajie Hou; Zhe Lin; Ming Yao; Runqiu Jiang; Youjing Wang; Yun Gao; Qing Shao; Lei Deng; Yun Chen; Beicheng Sun
Journal:  Cell Mol Immunol       Date:  2013-05-20       Impact factor: 11.530

2.  HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages.

Authors:  Valentina Vongrad; Jochen Imig; Pejman Mohammadi; Shivendra Kishore; Lukasz Jaskiewicz; Jonathan Hall; Huldrych F Günthard; Niko Beerenwinkel; Karin J Metzner
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

3.  Jianpi-Huayu Formula Inhibits Development of Hepatocellular Carcinoma by Regulating Expression of miR-602, Which Targets the RASSF1A Gene.

Authors:  Yajing Huang; Cheng Zhou; Huihong Wen; Yongxu Chen; Yingjie Xie; Xiaohe Lan; Juze Lin; Xuhui Huang; Yousheng Mo; Cong Yang; Qi Wang; Changjun Wang
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.